Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Fiche du document
1 mars 2022
- doi: 10.1515/pp-2022-0102
- issn: 2364-768X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1515/pp-2022-0102
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35602919
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2364-768X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_678E7F75FE912
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
TherapyCiter ce document
O. Sgarbura et al., « Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC). », Serveur académique Lausannois, ID : 10.1515/pp-2022-0102
Métriques
Partage / Export
Résumé
Safe implementation and thorough evaluation of new treatments require prospective data monitoring and standardization of treatments. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising alternative for the treatment of patients with peritoneal disease with an increasing number of suggested drug regimens. The aim was to reach expert consensus on current PIPAC treatment protocols and to define the most important research topics. The expert panel included the most active PIPAC centers, organizers of PIPAC courses and principal investigators of prospective studies on PIPAC. A comprehensive literature review served as base for a two-day hybrid consensus meeting which was accompanied by a modified three-round Delphi process. Consensus bar was set at 70% for combined (strong and weak) positive or negative votes according to GRADE. Research questions were prioritized from 0 to 10 (highest importance). Twenty-two out of 26 invited experts completed the entire consensus process. Consensus was reached for 10/10 final questions. The combination of doxorubicin (2.1 mg/m 2 ) and cisplatin (10.5 mg/m 2 ) was endorsed by 20/22 experts (90.9%). 16/22 (72.7%) supported oxaliplatin at 120 with potential reduction to 90 mg/m 2 (frail patients), and 77.2% suggested PIPAC-Ox in combination with 5-FU. Mitomycin-C and Nab-paclitaxel were favoured as alternative regimens. The most important research questions concerned PIPAC conditions (n=3), standard (n=4) and alternative regimens (n=5) and efficacy of PIPAC treatment (n=2); 8/14 were given a priority of ≥8/10. The current consensus should help to limit heterogeneity of treatment protocols but underlines the utmost importance of further research.